VIRAGEN TO PRESENT MULTIFERON TRIAL RESULTS

Viragen announced that data from its Phase II/III clinical study evaluating Multiferon, natural human alpha interferon, for the adjuvant treatment of malignant melanoma will be presented at the Sixth World Congress on Melanoma, to be held in Vancouver, Canada.

Multiferon is a highly purified, multi-subtype, natural human alpha interferon. It has been marketed in 10 international markets for the first-line or rescue therapy of a broad range of infectious diseases and cancers.